Trial Profile
Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2017
Price :
$35
*
At a glance
- Drugs Miravirsen (Primary) ; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Roche
- 05 Sep 2017 Status changed from active, no longer recruiting to completed.
- 29 May 2015 New trial record